Clinical Trial Update: Study to Assess the Safety, Pharmacokinetics, and Antiviral Activity of Repeat Doses of GSK2878175 in Subjects With Chronic Hepatitis C. [Phase 1]

View source ↗

Summary

Phase 1 study of repeat-dose GSK2878175 in chronic hepatitis C completed; assesses safety, pharmacokinetics, and antiviral activity.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• GSK2878175

Snippet

Sponsor: GlaxoSmithKline | Conditions: Hepatitis C, Chronic | Phase 1 | Status: COMPLETED